Foghorn Therapeutics Inc. Deferred Tax Assets, Net of Valuation Allowance
Foghorn Therapeutics Inc. (FHTX) had Deferred Tax Assets, Net of Valuation Allowance of $0 as of 2025-12-31, per its 10-K filed 2026-03-11.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance
us-gaap:DeferredTaxAssetsNet · last filed 2026-03-11
- 2025-12-31: Deferred Tax Assets, Net of Valuation Allowance $0.00.
- 2024-12-31: Deferred Tax Assets, Net of Valuation Allowance $0.00.
- 2023-12-31: Deferred Tax Assets, Net of Valuation Allowance $0.00.
- 2022-12-31: Deferred Tax Assets, Net of Valuation Allowance $0.00.
| Period end | Deferred Tax Assets, Net of Valuation Allowance |
|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-03-11 |
| 2024-12-31 | $0.00 10-K · filed 2026-03-11 |
| 2023-12-31 | $0.00 10-K · filed 2025-03-06 |
| 2022-12-31 | $0.00 10-K · filed 2024-03-07 |
| 2021-12-31 | $0.00 10-K · filed 2023-03-09 |
| 2020-12-31 | $0.00 10-K/A · filed 2022-08-09 |
| 2019-12-31 | $0.00 10-K · filed 2021-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |